XGen Pharmaceuticals DJB, Inc. is excited for another new product release!
Announcing the launch of Eribulin Mesylate Injection!
- 1 mg/2 mL (0.5 mg/mL) (NDC#39822-2080-1)
“With this launch of Eribulin Mesylate Injection, we are proud to add another oncology product to our growing portfolio”, stated Ed Vanderbeck, President of XGen Pharmaceuticals DJB. “We will remain committed to the development of acute care therapies in the areas of oncology, cardiovascular medicine and infectious disease. Our health depends on it.”